| CAT # | Product Name | Description |
| CPD100616 | Emricasan | Emricasan, also known as IDN 6556 and PF 03491390, is a first-in-class caspase inhibitor in clinical trials for the treatment of liver diseases. Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. IDN6556 facilitates marginal mass islet engraftment in a porcine islet autotransplant model. Oral IDN-6556 may lower aminotransferase activity in patients with chronic hepatitis C. Orally-administered PF-03491390 is retained in the liver for prolonged periods with low systemic exposure, exerting a hepatoprotective effect against alpha-fas-induced liver injury in a mouse model. |
| CPD100615 | Q-VD-Oph | QVD-OPH, also known as Quinoline-Val-Asp-Difluorophenoxymethylketone, is a broad spectrum caspase inhibitor with potent antiapoptotic properties. Q-VD-OPh prevents neonatal stroke in P7 rat: a role for gender. Q-VD-OPh has anti-leukemia effects and can interact with vitamin D analogs to increase HPK1 signaling in AML cells. Q-VD-OPh reduces trauma-induced apoptosis and improves the recovery of hind-limb function in rats after spinal cord injury |
| CPD100614 | Z-DEVD-FMK | Z-DEVD-fmk is a cell-permeable, irreversible inhibitor of caspase-3. Caspase-3 is a cysteinyl aspartate-specific protease which plays a central role in apoptosis. |
| CPD100613 | Z-IETD-FMK | MDK4982, also known as Z-IETD-FMK, is a potent, cell-permeable, irreversible inhibitor of caspase-8 and granzyme B., The Caspase-8 Inhibitor II controls the biological activity of Caspase-8. MDK4982 effectively inhibits influenza virus-induced apoptosis in HeLa cells. MDK4982 also inhibits granzyme B. MDK4982 has CAS#210344-98-2. |
| CPD100612 | Z-VAD-FMK | Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor. Z-VAD-FMK inhibits caspase processing and apoptosis induction in tumor cells in vitro (IC50 = 0.0015 - 5.8 mM). |
| CPD100611 | Belnacasan | Belnacasan, also known as VX-765, is designed to inhibit Caspase, which is an enzyme that controls the generation of two cytokines, IL-1b and IL-18. VX-765 has been shown to inhibit acute seizures in preclinical models. In addition, VX-765 has shown activity in preclinical models of chronic epilepsy. VX-765 had been dosed in over 100 patients in phase-I and phase-IIa clinical trials relating to other diseases, including a 28-day phase-IIa clinical trial in patients with psoriasis. It has completed the treatment phase of a phase-IIa clinical trial of VX-765 that enrolled approximately 75 patients with treatment-resistant epilepsy. The double-blind, randomized, placebo-controlled clinical trial was designed to evaluate the safety, tolerability and clinical activity of VX-765. |